We aim to cure chronic diseases and positively impact millions of lives
At Nouvogenes Therapeutics, we are driven by a bold vision: to transform the treatment of chronic diseases through precision gene editing. Using cutting-edge CRISPR technology, our clinical-stage therapies target the root cause of conditions, offering not just incremental improvements, but the possibility of a one-time treatment that could free patients from a lifetime of care, complications, and clinical dependency. With a growing pipeline of gene therapy candidates, we are committed to advancing science that restores health, reduces suffering, and redefines what’s possible for patients.
Nouvogenes Therapeutics’s News Room
Pipeline
Our pipeline is built on the power of CRISPR gene editing to deliver transformative therapies for patients. Our lead program targets Transfusion-Dependent Thalassemia (TDT), a condition with significant unmet medical need, and is currently advancing through clinical development. Behind it, we are developing a robust portfolio of next-generation gene therapies. Each program reflects our commitment to precision, durability, and meaningful patient impact.
The Science of CRISPR
At the heart of our innovation is CRISPR—a groundbreaking gene editing technology that enables precise, targeted changes to the DNA that causes disease. This Nobel Prize-winning science has unlocked a new era in medicine, making it possible to correct genetic mutations at their source. At Nouvogenes Therapeutics, we harness the precision and versatility of CRISPR to develop therapies designed for long-term, curative impact. Our scientific approach is rooted in deep expertise, rigorous research, and a commitment to safety and efficacy.
Target Diseases
Our initial focus is on Transfusion-Dependent Beta-Thalassemia, an inherited blood disorder that requires lifelong blood transfusions and places a heavy burden on patients and families. Despite advances in care, current treatments only manage the symptoms—without addressing the root cause. At Nouvogenes Therapeutics, we are developing gene therapies with the goal of eliminating the need for chronic transfusions and offering a durable, potentially curative solution.